Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615949 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
A Phase 2 study, sponsored by Cardiol Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04615949: Clinical Trial Phase 2 study, sponsored by Cardiol Therapeutics.
NCT04615949 is a Phase 2 study that was terminated before completion, run by Cardiol Therapeutics. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04615949, a Phase 2 study, was terminated before completion, sponsored by Cardiol Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
Primary Outcome
Proportions of patients in each group not having one of the outcome measures as described above (All-cause mortality, requirement for ICU admission and/or ventillatory support and cardiovascular complications)
Interventions
- DRUG Placebo
- DRUG Cannabidiol, pharmaceutically produced with < 5 ppm THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 2 |
Why NCT04615949 stopped before completion
NCT04615949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04615949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04615949 about?
NCT04615949 is a clinical study titled "Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors". Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
What is the current status of trial NCT04615949?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-04-30. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT04615949?
The interventions under investigation include: Placebo (DRUG), Cannabidiol, pharmaceutically produced with < 5 ppm THC (DRUG).
Who is sponsoring clinical trial NCT04615949?
This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04615949's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI